Association between cervical lesion grade and micronucleus frequency in the Papanicolaou test

HUMAN AND MEDICAL GENETICS

SHORT COMMUNICATION

Association between cervical lesion grade and micronucleus frequency in the Papanicolaou test

Caroline Tanski Bueno^I; Cláudia Maria Dornelles da Silva^II; Regina Bones Barcellos^II; Juliana da Silva^III; Carla Rossana dos Santos^I; João Evangelista Sampaio Menezes^IV; Honório Sampaio Menezes^{IV, V}; Maria Lucia Rosa Rossetti^{II, VI}

^ICurso de Graduação em Biomedicina, Universidade Luterana do Brasil, Canoas, RS, Brazil

^IICentro de Desenvolvimento Científico e Tecnológico, Fundação Estadual de Produção e Pesquisa em Saúde, Porto Alegre, RS, Brazil

^IIILaboratório de Genética Toxicológica, Programa de Pós-graduação em Genética e Toxicologia Aplicada, Universidade Luterana do Brasil, Canoas, RS, Brazil

^IVLaboratório Cediclin, Canoas, RS, Brazil

^VInstituto de Cardiologia, Fundação Universidade de Cardiologia, Porto Alegre, RS, Brazil

^VIPrograma de Pós-graduação em Genética e Toxicologia Aplicada, Universidade Luterana do Brasil, Canoas, RS, Brazil

^{Send correspondence to}

ABSTRACT

The aim of this study was to evaluate the association between the frequency of micronuclei (MN) and the cellular changes detected in the conventional Papanicolaou test. One hundred and seventy-four Papanicolaou test smears with cellular changes were examined. MN screening was done in cytopathological smears by counting 1,000 cervical cells in a light microscope. MN frequencies were significantly higher in the group with cellular changes compared to the control group (p < 0.001). The mean MN frequencies were 0.95 ± 1.12 (mean ± SD) in the control group (n = 223), 2.98 ± 1.20 in individuals with atypical squamous cells of undetermined significance (ASC-US) (n = 50), 4.04 ± 1.45 in cervical intraepithelial neoplasia (CIN) I (n = 52), 5.97 ± 1.83 in CIN II (n = 30), 7.29 ± 1.55 in CIN III (n = 17) and 8.64 ± 1.55 in invasive cancer (n = 25). These findings suggest that MN monitoring should be included as an additional criterion for the early detection of cytogenetic damage in routine examinations. This monitoring should be done in the same smear as used for cytopathological examination. More specific and systematic studies are necessary to confirm this proposal.

Keywords: cervical cancer, cervical lesions, micronucleus, Papanicolaou test.

Cervical cancer is the third most common cancer among women worldwide (Jemal et al., 2011) and the second cause of cancer mortality in Brazilian women (WHO/ICO, 2013). Among all known types of cancer, cervical cancer has some of the best prospects in terms of prevention and cure: when diagnosed early, cervical cancer has up to a 100% chance of cure. However, about 80% of cervical cancer cases occur in developing countries, where neither population-based screening nor optimal treatment is available (NIH report, 2010).

The Papanicolaou (Pap) test is the most common and inexpensive screening method for cervical cancer and has played an effective role in reducing the prevalence and mortality rates of this cancer among women (Peirson et al., 2013). Given the slow progression of cervical cancer, correct diagnosis is possible in asymptomatic women. In Brazil, the Pap test is the screening strategy recommended by the Federal Health Ministry, with priority for women 25-59 years old (INCA, 2006). Although Brazil was one of the first countries to adopt the Pap test, the disease remains a serious public health problem. From 2003 to 2008, ~87% of Brazilian women were covered by the Pap test (BRATS, 2011). In a recent study of 2,030 women in southern Brazil, 10.9% had never been tested and 12.2% had not been tested in the last three years (Bairros et al., 2011).

Human papillomavirus (HPV) is the etiological agent of cervical intraepithelial neoplasia (CIN) and cervical cancer. Some studies have shown that women infected with HPV strains 16 or 18 have a higher rate of progression from CIN to cancer (Bernard et al., 2013). Although HPV infection is responsible for virtually all cervical cancers, in some situations the presence of the virus is not linked to the cellular changes visualized by microscopy. Indeed, one of the most important deficiencies of the Pap test is its limited sensitivity in detecting cervical cancer precursors, coupled with the subjective interpretation of results. As a result, false negatives account for 10-50% of Pap test results (Dehner, 1993). Complementary methods aimed at increasing the sensitivity of screening for cervical cancer have been described, including high-risk HPV testing (Abreu et al., 2012) and micronucleus (MN) identification (Aires et al., 2011; Gayathri et al., 2012). Although HPV testing is considered the gold standard for diagnosing this viral infection and has the potential to improve the effectiveness of screening programs, its implementation must still be kept low-cost in order to be used in low-income populations (Abreu et al., 2012).

The presence of MN is a biomarker that has been successfully used to screen populations at risk of cancer and is a sensitive indicator of genetic damage (Samanta and Dey, 2012). MN are small, additional nuclei formed by the exclusion of chromosomal fragments (clastogenesis) or whole chromosomes that are not incorporated into the main nuclei because of mitotic malfunction (aneugenesis) (Fenech et al., 2011).

Since the evolution from CIN I to CIN III is accompanied by enhanced genetic instability (Hopman et al., 2004), the presence of MN has been used, in combination with cytological findings, as a biomarker of the risk of cervical cancer (Pandey et al., 2011). Previous studies have shown that the frequency of MN increases in parallel with the severity of phenotypic changes in the transition from low-grade to high-grade lesions (Guzmán et al., 2003; Gayathri et al., 2012). In this study, we examined the association between MN frequency and cellular changes detected in the Pap test in a large cohort of women from southern Brazil.

Three hundred and ninety-seven smears were analyzed in the Cediclin Laboratory (Canoas, RS, Brazil) from October 2008 to November 2009. The smears were stained using standard Pap methodology and classified using the criteria described by the Brazilian nomenclature for cervical reports (INCA, 2006). Smears were selected based on the respective original cytological examination report and the results were classified as normal, atypical squamous cells of undetermined significance (ASC-US), CIN I, CIN II, CIN III and invasive cancer (IC). Normal smears, i.e., those in which no cellular change was observed, were used as the control group. The classification ASC-H was not included because of the lack of smears with this diagnosis. This work was approved by the Committee for Ethics in Research at ULBRA/Canoas (protocol no. CEP-2008-601H).

MN screening was done in all selected cytopathological (CP) smears (conventional Pap test) by counting 1,000 cervical squamous cells with a light microscope at a magnification of 1000x (100x objective and 10x eyepiece), according to the criteria defined by Tolbert et al. (1992). The MN identification criteria were: (a) a chromatin structure similar to and color intensity similar or lighter than that observed in the main nucleus, (b) an evident edge, similar to a nuclear membrane, (c) a round shape, (d) an intracytoplasmic location and (d) a diameter < 20% of the main nucleus.

The smears evaluated at the Cediclin Laboratory were sent to the Biological Research Institute of the Central Laboratory of Rio Grande do Sul (IPB/LACEN-RS) for external monitoring of quality control. The Brazilian Ministry of Health advocates that a minimum of 10% of the performed exams should be revised (INCA, 2002). The results for MN detection were compared with those for the Pap test of the same smear.

The relationship between MN frequency and cellular changes detected in the Pap test was examined using the software GraphPad PRISM 5.0 (GraphPad Inc., San Diego, CA). All results were expressed as the mean ± standard deviation. Analysis of variance (ANOVA) was used to compare the MN frequencies among the different lesion classes (ASC-US, CIN I, CIN, II, CIN III and invasive cancer) and Dunn's post-hoc test was used to compare the groups. A non-parametric ANOVA (Kruskall-Wallis test) was used to analyze the data when they were not homoscedastic or normal. P-values < 0.05 were considered statistically significant.

Of the smears analyzed, 223 had normal CP results (control group) and 174 had cellular changes (case group). The smears with cellular changes consisted of 50 cases of ASC-US, 52 of CIN I, 30 of CIN II, 17 of CIN III and 25 of cervical cancer. Micronuclei were observed in all groups, even in the controls (Figure 1). The MN frequencies in the different groups were 0.95 ± 1.12 (n = 223) in the control group, 2.98 ± 1.20 (n = 50) in individuals with ASC-US cellular changes, 4.04 ± 1.45 (n = 52) in CIN I, 5.97 ± 1.83 (n = 30) in CIN II, 7.29 ± 1.55 (n = 17) in CIN III and 8.64 ± 1.55 (n = 25) in cervical cancer. These frequencies were significantly higher in groups with cellular changes compared to the control group (p < 0.001) (Figure 2).

The increase in MN frequency observed here could be related to both clastogenic and aneugenic events. The genetic instability caused by HPV infection involves the expression of viral oncogenes E6 and E7 (Duensing et al., 2000; Duensing and Munger, 2004). Whereas E6 expression may result in failed cytokinesis, E7 expression may uncouple centrosome duplication from cell division. Although alterations in centrosome number are random and unpredictable and can lead to chromosomal instability, centrosome status has become a useful parameter for monitoring neoplastic progression and for assessing patient prognosis for some tumor types. In addition, in the absence of a functional TP53 gene, cells may become aneuploid (Braakhuis et al., 2013).

Few studies have scored MN in cervical precancerous and cancerous conditions. To our knowledge, the present study involves one of the largest samples and is the first to report on a population of women from southern Brazil. The MN frequencies observed here were significantly higher in the groups with cellular changes compared to the control group, in agreement with previous case-control studies (Leal-Garza et al., 2002; Gandhi and Kaur, 2003; Cortés-Gutiérrez et al., 2010; Gayathri et al., 2012).

As shown here, there was a positive linear correlation between the number of MN and the risk of cervical cancer. Women with CIN III alterations had higher MN frequencies than those with CIN II lesions, who in turn had higher MN frequencies than CIN I patients. In a study of exfoliated cells from 101 patients the MN frequency was found to be higher in women with some grade of CIN lesions (CIN I, II and III) and increased with the severity of cellular damage (Campos et al., 2008). A high frequency of MN that increased with the severity of the lesions was also observed in a study of 221 slides involving CIN I, CIN II, CIN III and invasive cancer (Gayathri et al., 2012). Guzmán et al. (2003) confirmed the existence of a relationship between lesion grade and MN frequency in epithelial cells of patients who had undergone CP. Although there was no significant increase in MN frequencies in the progression from mild to severe lesions, there was a marked increase in the frequency of micronucleated cells compared to healthy subjects. In contrast, other studies have reported no significant difference between the number of MN and the stages of cervical cancer (Leal-Garza et al., 2002; Gandhi and Kaur, 2003).

One of the challenges of the Pap test is to detect lesions with a high risk of progressing to cancer, particularly since most cellular lesion regress spontaneously without treatment. In this context, it is reasonable to assume that the definition of an MN cell ratio could be useful in discriminating between patients with a low risk and a high risk of developing cervical cancer. The sensitivity of the Pap test in detecting high grade lesions (CIN II and CIN III) has been shown to be only 55.4%, with a specificity of 96.8% (Mayrand et al., 2007). The usefulness of the MN assay for detecting other types of cancer has also been investigated. A recent meta-analysis revealed a significant increase in the basal MN frequency in relation to breast cancer, leading to the suggestion that this test be used to screen women with a family history of this cancer (Cardinale et al., 2012).

The results described here suggest that MN monitoring could be incorporated into routine screening procedures as an additional criterion for the early detection of cytogenetic damage based on the same smear as used in cytopathological analyses. Such monitoring would improve the sensitivity and specificity of the screening and reduce the rate of false-negatives. However, additional detailed, systematic studies are needed to confirm this suggestion.

Acknowledgments

This work was supported by Cediclin Laboratory and the Lutheran University of Brazil (ULBRA).

Internet Resources

Received: January 31, 2014;

Accepted: April 10, 2014.

Associate Editor: Daisy M.F. Salvadori

License information: This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

• Abreu AL, Souza RP, Gimenes F and Consolaro ME (2012) A review of methods for detecting human papillomavirus infection. Virol J 9:262.
• Aires GM, Meireles JR, Oliveira PC, Oliveira JL, Araújo EL, Pires BC, Cruz ES, Jesus NF, Pereira CA and Cerqueira EM (2011) Micronuclei as biomarkers for evaluating the risk of malignant transformation in the uterine cervix. Genet Mol Res 10:1558-1564.
• Bairros FS, Meneghel SN, Dias-da-Costa JS, Bassani DG, Menezes AM, Gigante DP and Olinto MT (2011) Racial inequalities in access to women's health care in southern Brazil. Cad Saude Public 27:2364-2372.
• Bernard E, Pons-Salort M, Favre M, Heard I, Delarocque-Astagneau E, Guillemot D and Thiébaut AC (2013) Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: A meta-analysis of observational studies. BMC Infect Dis 13:e373.
• Braakhuis B, Rietbergen M, Buijze M, Snijders P, Bloemena E, Brakenhoff R and Leemans C (2013) TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients. Oral Dis [E-Pub ahead of print].
• Campos LMR, Luz Dias FD, Antunes LM and Murta EF (2008) Prevalence of micronuclei in exfoliated uterine cervical cells from patients with risk factors for cervical cancer. São Paulo Med J 126:323-328.
• Cardinale F, Bruzzi P and Bolognesi C (2012) Role of micronucleus test in predicting breast cancer susceptibility: A systematic review and meta-analysis. Br J Cancer 106:780-790.
• Cortés-Gutiérrez EI, Dávila-Rodríguez MI, Vargas-Villarreal J, Hernández-Garza F and Cerda-Flores RM (2010) Association between human papilloma virus-type infections with micronuclei frequencies. Prague Med Rep 111:35-41.
• Dehner LP (1993) Cervicovaginal cytology, false-negative results, and standards of practice. Am J Clin Pathol 99:45-47.
• Duensing S, Lee LY, Duensing A, Basile J, Piboonniyom S, Gonzalez S, Crum CP and Munger K (2000) The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci USA 97:10002-10007.
• Duensing S and Münger K (2004) Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int J Cancer 109:157-162.
• Fenech M, Kirsch-Volders M, Natarajan AT, Surralles J, Crott JW, Parry J, Norppa H, Eastmond DA, Tucker JD, et al. (2011) Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis 26:125-132.
• Gandhi G and Kaur B (2003) Elevated frequency of micronuclei in uterine smears of cervix cancer patients. Caryologia 56:217-222.
• Gayathri B, Kalyani R, Hemalatha A and Vasavi B (2012) Significance of micronucleus in cervical intraepithelial lesions and carcinoma. J Cytol 29:236-240.
• Guzmán P, Sotelo-Regil RC, Mohar A and Gonsebatt ME (2003) Positive correlation between the frequency of micronucleated cells and dysplasia in Papanicolaou smears. Environ Mol Mutagen 41:339-343.
• Hopman AH, Smedts F, Dignef W, Ummelen M, Sonke G, Mravunac M, Vooijs GP, Speel EJ and Ramaekers FC (2004) Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 202:23-33.
• INCA (2006) Brazilian nomenclature for cervical cytology reports and guidelines J Bras Patol Med Lab 42:351-373.
• Jemal A, Bray F, Center MM, Ward E and Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90.
• Leal-Garza CH, Cerda-Flores RM, Leal-Elizondo E and Cortés-Gutiérrez EI (2002) Micronuclei in cervical smears and peripheral blood lymphocytes from women with and without cervical uterine cancer. Mutat Res 515:57-62.
• Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL and the Canadian Cervical Cancer Screening Trial Study Group (2007) Human papillomavirus DNA vs. Papanicolaou screening tests for cervical cancer. N Engl J Med 357:1579-1588.
• Pandey D, Putteddy S and Rao S (2011) Micronucleus assay as a triage tool for bordeline cases of cervical dysplasia. Sri Lanka J Obst Gynaecol 33:104-111.
• Peirson L, Fitzpatrick-Lewis D, Ciliska D and Warren R (2013) Screening for cervical cancer: A systematic review and meta-analysis. Syst Rev 2:35.
• Samanta S and Dey P (2012) Micronucleus and its applications. Diagn Cytopathol 40:84-90.
• Tolbert PE, Shy CM and Allen JW (1992) Micronuclei and other nuclear anomalies in buccal smears: Methods development. Mutat Res 271:69-77.
• BRATS (Boletim Brasileiro de Avaliação em Tecnologia em Saúde) (2011) Câncer de colo de útero: a vacina para prevenção do HPV e o desafio para a melhoria da qualidade do rastreamento no Brasil. http://portal.anvisa.gov.br/wps/wcm/connect/4bbac7804a14f133a713afaa19e2217c/BRATS17.pdf?MOD=AJPERES (March 21, 2014).
• INCA (National Cancer Institute José Alencar Gomes da Silva) (2002) Prevenção do câncer do colo do utero – Manual técnico. http://bvsms.saude.gov.br/bvs/publicacoes/inca/manual_profissionaisdesaude.pdf (January 29, 2014).
• NIH report (2010) http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76 (January 27, 2014).
  » link
• WHO/ICO (2013) Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers, Fact sheet 2013. http://www.hpvcentre.net/statistics/reports/BRA_FS.pdf (January 28, 2014).

Publication Dates

• Publication in this collection
  22 Sept 2014
• Date of issue
  Sept 2014

History

• Received
  31 Jan 2014
• Accepted
  10 Apr 2014